Affiliations 

  • 1 School of Bioengineering & Biosciences, Lovely Professional University, Phagwara, Punjab, 144411, India
  • 2 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India
  • 3 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia
  • 4 School of Pharmacy & Pharmaceutical Sciences, Ulster University, Coleraine, County, Londonderry, BT52 1SA, Northern Ireland, UK
  • 5 Department of Chemistry, University of Petroleum & Energy Studies, Dehradun, 248007, India
  • 6 Centre for Inflammation, Centenary Institute & University of Technology Sydney, School of Life Sciences, Faculty of Science, Sydney, Australia
  • 7 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Future Med Chem, 2022 Feb;14(4):271-288.
PMID: 35019757 DOI: 10.4155/fmc-2021-0081

Abstract

Chronic respiratory disorders affect millions of people worldwide. Pathophysiological changes to the normal airway wall structure, including changes in the composition and organization of its cellular and molecular constituents, are referred to as airway remodeling. The inadequacy of effective treatment strategies and scarcity of novel therapies available for the treatment and management of chronic respiratory diseases have given rise to a serious impediment in the clinical management of such diseases. The progress made in advanced drug delivery, has offered additional advantages to fight against the emerging complications of airway remodeling. This review aims to address the gaps in current knowledge about airway remodeling, the relationships between remodeling, inflammation, clinical phenotypes and the significance of using novel drug delivery methods.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.